Clinical Trial Update: PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PD-L1 t-haNK with NAI IL-15sa and cetuximab for recurrent/metastatic head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• NAI IL-15sa (Interleukin-15 superagonist)
• PD-L1 t-haNK

Snippet

Sponsor: Glenn J. Hanna | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING